Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs
PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, UK, and is a spinoff of the University of Cambridge.
Discover how we are reimagining small molecule therapeutics through AI at pharmenabletx.com and connect with us on LinkedIn.
At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 7 Jun 2021 31 Jan 2024 | | |
Telefónica Startup accelerator & VC, Telecommunications | Telefónica Startup accelerator & VC, Telecommunications | Other 4 Oct 2018 | | |
Cambridge Enterprise Startup accelerator & VC, Higher Education | Cambridge Enterprise Startup accelerator & VC, Higher Education | Capitalistic Not partnership Not event 3 Jul 2020 24 Oct 2022 | | |